Hemlibra (Emicizumab)

Hemlibra is indicated for patients with hemophilia A, including those who have developed inhibitors against factor VIII.

• Treatment of hemophilia A with factor VIII inhibitors to reduce bleeding episodes.
• Prophylactic therapy for hemophilia A patients without inhibitors to maintain baseline clotting.
• Use as a long‑term preventive option in adults and children with severe hemophilia A.
• May be considered when traditional factor VIII replacement is ineffective or impractical.

Clinical studies have identified a range of adverse events associated with emicizumab therapy, which are categorized by frequency and severity.

Common

• Injection site reactions such as redness, swelling, or pain.
• Headache or mild dizziness.
• Upper respiratory tract symptoms including nasal congestion or sore throat.
• Transient increase in liver enzymes.
• Mild fatigue or malaise.

Serious

• Thrombotic microangiopathy, especially when combined with activated prothrombin complex concentrates.
• Uncontrolled thrombotic events or clot formation.
• Severe allergic reactions, including anaphylaxis.
• Significant elevation of liver function tests requiring medical evaluation.

Before initiating Hemlibra, clinicians should evaluate patient history and monitor specific parameters to mitigate potential risks associated with the therapy.

• Assess for a history of thrombotic disorders or cardiovascular disease.
• Perform baseline liver function tests and repeat periodically during treatment.
• Avoid concurrent use of activated prothrombin complex concentrates unless medically necessary.
• Monitor for signs of allergic reactions, especially after the first few injections.
• Counsel patients on proper injection technique to reduce local site complications.
• Consider pregnancy status; data are limited, and benefits must be weighed against unknown risks.

Emicizumab may interact with other hemostatic agents and medications that affect coagulation, requiring careful management.

Avoid

• Activated prothrombin complex concentrates (aPCC) used for breakthrough bleeding, due to increased thrombotic risk.
• High‑dose recombinant activated factor VII (rFVIIa) in combination with aPCC.

Use with caution

• Other bypassing agents such as rFVIIa alone, which may still elevate clotting potential.
• Antifibrinolytic drugs (e.g., tranexamic acid) when used concurrently with other pro‑coagulants.
• Medications that influence liver enzymes, as they may affect emicizumab metabolism.
• Immunosuppressive therapies that could alter antibody response.
• Vaccines containing live attenuated viruses, pending clinical judgment.